Just four years after its foundation, Ireland's Inflazome Ltd. and its portfolio of NLRP3 inhibitors targeting a wide range of chronic inflammatory conditions has been acquired by Roche Holding AG.
The Swiss major has splashed out €380m upfront to buy the firm which was founded in 2016 by Matt Cooper from the University of Queensland, Australia and Luke O'Neill from Trinity College in Dublin
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?